Exelixis
EXEL
#2191
Rank
$5.60 B
Marketcap
$17.39
Share price
2.05%
Change (1 day)
9.79%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2022 (TTM): $0.38 B

According to Exelixis's latest financial reports the company's current earnings (TTM) are $0.38 B. In 2021 the company made an earning of $0.29 B an increase over its 2020 earnings that were of $0.13 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2001 to 2022

Annual earnings

Year Earnings Change
2022 (TTM)$0.38 B30.48%
2021$0.29 B124.82%
2020$0.13 B-67.14%
2019$0.39 B-11.94%
2018$0.45 B185.09%
2017$0.15 B-312.79%
2016-$74.53 M-56.08%
2015-$0.17 B-36.86%
2014-$0.27 B9.75%
2013-$0.25 B65.96%
2012-$0.15 B-269.64%
2011$86.97 M-207.98%
2010-$80.55 M-42.17%
2009-$0.14 B-20.66%
2008-$0.18 B-9.5%
2007-$0.2 B53.54%
2006-$0.13 B33.25%
2005-$94.81 M-30.92%
2004-$0.14 B44.29%
2003-$95.12 M10.37%
2002-$86.19 M25.55%
2001-$68.65 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
$22.51 B 5,767.38%๐Ÿ‡บ๐Ÿ‡ธ USA
$34.92 B 8,999.27%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.72 B 1,913.81%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.65 B 2,154.62%๐Ÿ‡ซ๐Ÿ‡ท France
$17.77 B 4,531.58%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.71 B 1,909.38%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.58 B 1,615.43%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$52.46 M-113.67%๐Ÿ‡บ๐Ÿ‡ธ USA
-$29.04 M-107.57%๐Ÿ‡บ๐Ÿ‡ธ USA